Mesalazine Teva

Mesalazine, the active ingredient in Mesalazine Teva, is a 5-aminosalicylic acid (5-ASA) presented as a tablet for gastroenteral use. It treats ulcerative colitis and Crohn's disease in adult patients by reducing intestinal inflammation. GNH USA supplies Mesalazine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalazine Teva belongs to the 5‑ASA class and is used to manage inflammatory bowel disease. - Ulcerative colitis: reduces mucosal inflammation and helps maintain clinical remission. - Crohn's disease: controls intestinal inflammation and alleviates disease‑related symptoms. - Maintenance therapy: supports long‑term disease control after induction of remission.

Mesalazine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Abdominal pain or cramping - Headache - Flatulence or bloating - Diarrhea - Rash or mild skin irritation

Serious or Rare Side Effects: - Acute pancreatitis - Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome) - Blood dyscrasias (e.g., neutropenia, thrombocytopenia) - Hepatotoxicity (elevated liver enzymes, hepatitis) - Interstitial nephritis or renal impairment - Severe colitis or perforation

Before initiating therapy, clinicians should consider several safety measures. - Renal function monitoring: assess baseline creatinine and periodically re‑evaluate. - Hepatic function monitoring: check liver enzymes before and during treatment. - Hypersensitivity assessment: discontinue if signs of severe allergic reaction appear. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Elderly patients: start at lower doses and monitor closely for toxicity. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mesalazine can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Azathioprine or 6‑mercaptopurine: heightened myelosuppression. - Live vaccines: reduced efficacy and potential infection risk.

Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive effectiveness.